Connor Iapoce

A recent analysis suggests that incorporating retinal and choroidal microvascular metrics may improve the identification of eyes with no diabetic retinopathy from those with DR.

A lack of a significant refractive error and visiting an optometrist rather than an ophthalmologist were factors associated with a missed diagnosis of primary open-angle glaucoma, according to a recent analysis.

The use of other antihypertensive medications, lipid-lowering medications, antidepressants, or antidiabetic medications were not clearly associated with glaucoma in a recent analysis.

An analysis of real-life data indicates the role of adalimumab in reducing the frequency and/or severity of ocular flares in pediatric patients with non-infectious non-anterior uveitis.

A prospective study on patients with DR and CKD found no significant effect on renal function shortly after performing fluorescein angiography.

A recent analysis of patients with AMD detected no significant associations between AMD-associated variants and hemopexin levels.

A post-hoc analysis of the HARBOR trial suggests MNV type 3 was a strong risk factor for new macular atrophy development at month 24 in ranibizumab-treated eyes with nAMD.

Results suggest patients with age-related macular degeneration who have visual disability should be targets for risk factor management and disease prevention for cardiovascular disease.

An AI-based fundus screening system used in a real-world setting was able to distinguish between normal and abnormal ocular fundus and diagnose 5 prevalent ocular conditions.

Logistic regression analysis indicated that higher stages of urine albumin creatine ratio were significantly associated with diabetic retinopathy in patients with T2D and diabetic nephropathy.

The findings of a recent diagnostic study suggest that AI was able to infer the self-reported race of infants from retinal vessel maps, something human graders are unable to do.

A new study suggests ChatGPT may not provide substantial assistance in preparing for board certification at this time.

In this episode, Charles Wykoff, MD, PhD joins Dr. Sheth to provide insight into the recent landmark approval of pegcetacoplan injection (SYFOVRE™) for geographic atrophy, how clinical practice has changed as a result, and both the early struggles with and optimism for an ever-changing treatment landscape.

Retrospective data suggest a treat-and-extend regimen using brolucizumab is effective for improving outcomes in eyes with exudative AMD refractory to aflibercept.

Based on data presented at ARVO 2023, Parikh discusses how anti-VEGF biosimilars may increase both patient and overall healthcare costs.

Pending FDA approval, RVO would be the third indication for faricimab-svoa in addition to wet age-related macular degeneration and diabetic macular edema.

The approval, granted to Eyenovia, Inc, represents the first-approved fixed-dose combination of tropicamide and phenylephrine for inducing mydriasis for diagnostic procedures and short-term pupil dilation.

Intravitreal brolucizumab and aflibercept in eyes with nAMD were each linked to a significant decrease in the ocular blood flow 30 minutes after injection.

Intravitreal steroid treatment for DME was associated with no significant differences in BCVA, but a higher risk of IOP-related events, compared to anti-VEGF therapy.

Alterations in the compositions and metabolic functions of intestinal microbiota between AMD patients and healthy controls may help elucidate specific targets for AMD treatment.

A single-center study reports no significant difference in global peripapillary RNFL thickness in eyes treated with intravitreal brolucizumab during a short-term follow-up period after injection.

The 6-month RCT investigating submacular hemorrhage secondary to nAMD found that both treatment modalities showed clinical improvement of VA, but surgery did not provide a superior visual gain.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our April 2023 month-in-review features data on the association between social determinants of health and vision loss, preferences for AMD monitoring, and the launch of a new multimedia series.

At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.

At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.

At ARVO 2023, Elizabeth Rossin, MD, PhD, elaborates on genetic and biological pathways that may contribute to epiretinal membrane risk.

Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features top new studies, FDA approvals, and an overview of news surrounding Abbott readers.

A retrospective study of nearly 19,000 eyes presented at ARVO 2023 found patients with GA lost 2 lines of vision at year 3 and are at meaningful risk of nAMD.

At ARVO 2023, David Tabano, PhD, discussed the analysis of the largest real-world evaluation of treatment patterns and outcomes in DME patients treated with faricimab.